EVAX (Evaxion Biotech AS) Total Payout Ratio : 0.00 (As of Apr. 24, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Evaxion Biotech AS's current Total Payout Ratio is 0.00.

Evaxion Biotech AS Total Payout Ratio Historical Data

The historical data trend for Evaxion Biotech AS's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Total Payout Ratio Chart

Evaxion Biotech AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Payout Ratio

Get a 7-Day Free Trial

0.60

2.20

0.02

0.41

1.57

Evaxion Biotech AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Evaxion Biotech AS's Total Payout Ratio

For the Biotechnology subindustry, Evaxion Biotech AS's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evaxion Biotech AS's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's Total Payout Ratio falls into.

Save Embed

;

Save Embed

;

Evaxion Biotech AS Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Evaxion Biotech AS's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	16.55	+	0)	/	-10.567
	=	1.57

Evaxion Biotech AS's Total Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-3.629
	=	0.00

Evaxion Biotech AS Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dr. Neergaards Vej 5f, Hoersholm, DNK, 2970

Website

https://www.evaxion.ai

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are: EVX-01, EVX-03, and EVX-02, which are vaccine candidates being developed for the treatment of various solid cancers. In addition, the company is developing EVX-B1, EVX-B2, EVX-B3, EVX-V1, and multiple other vaccine candidates for various infectious diseases, such as cytomegalovirus, N.gonorrhoeae, bacterial pathogens, and others.